España
India
Italia
대한민êµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Arch Therapeutics
ARTH
OTCQB
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.3100
0.09
41.63%
Pre-Market: Oct 8, 4:06 PM EDT
Get Report
Comment
Arch Therapeutics (ARTH) Forecast
News
Earnings
Arch Therapeutics (ARTH) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Arch Therapeutics (OTC:ARTH) Stock
Arch Therapeutics Stock (OTC: ARTH)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, July 27, 2020
HC Wainwright & Co. Maintains Buy on Arch The...
Benzinga Newsdesk
Tuesday, March 24, 2020
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
Monday, October 28, 2019
Stocks That Hit 52-Week Lows On Monday
Lisa Levin
Friday, October 25, 2019
Stocks That Hit 52-Week Lows On Friday
Lisa Levin
Thursday, October 24, 2019
Stocks That Hit 52-Week Lows On Thursday
Lisa Levin
Monday, September 23, 2019
Stocks That Hit 52-Week Lows On Monday
Lisa Levin
Wednesday, March 14, 2018
Benzinga's Top Upgrades, Downgrades For March 14, 2018
Benzinga
IFS Securities Downgrades ARCH THERAPEUTICS INC by Arch Therapeutics, Inc. to Outperform
Benzinga
Monday, February 13, 2017
Rodman & Renshaw Initiates Coverage On Arch Therapeutics at Buy, Announces $2.50 Target
Benzinga
Thursday, November 06, 2014
Arch Therapeutics Reports Positive Preclinica...
Benzinga
Monday, September 08, 2014
Arch Therapeutics Announces Positive Preclini...
Benzinga
